Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia

Haematologica

Volumn 95, Issue 9, 2010, Pages 1441-1444

  Zenz, Thorsten ^a   Mertens, Daniel ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B LYMPHOCYTE RECEPTOR; BETA 2 MICROGLOBULIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN KAPPA CHAIN; RITUXIMAB; THYMIDINE KINASE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BIOPSY; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; EDITORIAL; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; MICROENVIRONMENT; OVERALL SURVIVAL; PATIENT CODING; PROGNOSIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC HYPERMUTATION;

CELL PROLIFERATION; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; MALE; RECEPTORS, ANTIGEN, B-CELL;

EID: 77956791364     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.027151     Document Type: Editorial

References (22)

1. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-64.
2. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.
3. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37-50.
4. Marincevic M, Cahill N, Gunnarsson R, Isaksson A, Mansouri M, Göransson H, et al. High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica. 2010;95(9):1519-25.
5. Giné E, Martinez A, Villamor N, López-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526-33.
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
8. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-70.
9. Tobin G, Thunberg U, Johnson A, Thorn I, Soderberg O, Hultdin M, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99(6):2262-4.
10. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4):1177-84.
11. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Busch R, Fingerle-Rowson G, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. ASH Annual Meeting Abstracts. 2008;112:781.
12. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-9.
13. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589-97.
14. Zenz T, Habe S, Denzel T, Winkler D, Dohner H, Stilgenbauer S. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance. Leukemia. 2008; 22(12):2257-8.
15. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. How I treat refractory CLL. Blood. 2006;107(4):1276-83.
16. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21(1):12-7.
17. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799-804.
18. Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, et al. Prognostic factors identify 3 risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010 May 29. [Epub ahead of print]
19. Stilgenbauer S, Eichhorst BF, Busch R, Zenz T, Winkler D, Buhler A, et al. Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC)-comprehensive analysis of the CLL4 trial of the GCLLSG. ASH Annual Meeting Abstracts. 2008;112:2089.
20. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-88.
21. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
22. Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009; 23(1):212-4.